Biotech Specialty Pharma

Transdel Pharmaceuticals

4225 Executive Square Suite 485
La Jolla, CA 92037 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Specialty pharmaceutical company developing non-invasive, topically delivered products.

Management John T. Lomoro, Acting Chief Executive Officer/Chief Financial Officer; Joachim P. H. Schupp, M.D., Chief Medical Officer; Terry Nida, Chief Business Officer

Click here for Financial Data
Keywords: dermatology, pain management

Comment


Updated: Aug. 22, 2013


Description

Transdel Pharmaceuticals, Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel cream formulation technology i......view more

Products / Services

Pharmaceutical - Ketotransdel is comprised of our proprietary Transdel drug delivery system and ketoprofen, a non-steroidal anti-inflammatory drug (NSAID). Ketotransdel, which has completed one Phase......view more

Technology / Differentiation

The Company's innovative-patented Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. The Company intends...view more

Market / Customers

The market for NSAIDs and COX-2 inhibitors in the United States may exceed $8 billion. Since the withdrawal of major COX-2 inhibitors in 2005, oral NSAIDs have captured a share of the multi-billion r......view more


Competitors / Substitutes / Alternatives

There are three topical NSAID products that have been launched into the market. Two of those were launched in 2008 and in 2010 another product was launched. With the launch of each product, the mark...view more

Strategy

We expect that Ketotransdel, if and when approved by the FDA, could become the first topical NSAID cream product available by prescription in the United States for acute pain management. We are seeki...view more

Revenue / Funding

Funding Status - To date, Transdel has raised approximately $11 million. In order to conduct the second Phase 3 trial and the other routine supportive tolerability/pharmacokinetic studies, which ar...view more

Status

Ketotransdel - Completed a Phase 3 trial in 2009 and reported that the Ketotransdel study demonstrated statistical significance in its primary endpoint in the modified Intent-To Treat (ITT) Analysis. ...view more

RELATED COMPANIES